When close to half the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or "P/S") below 1x, you may consider Green Thumb Industries Inc. (CSE:GTII) as a stock to potentially avoid with its 2.2x P/S ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the elevated P/S.
View our latest analysis for Green Thumb Industries
What Does Green Thumb Industries' P/S Mean For Shareholders?
There hasn't been much to differentiate Green Thumb Industries' and the industry's revenue growth lately. Perhaps the market is expecting future revenue performance to improve, justifying the currently elevated P/S. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
Want the full picture on analyst estimates for the company? Then our free report on Green Thumb Industries will help you uncover what's on the horizon.Is There Enough Revenue Growth Forecasted For Green Thumb Industries?
The only time you'd be truly comfortable seeing a P/S as high as Green Thumb Industries' is when the company's growth is on track to outshine the industry.
Taking a look back first, we see that the company managed to grow revenues by a handy 8.6% last year. This was backed up an excellent period prior to see revenue up by 48% in total over the last three years. So we can start by confirming that the company has done a great job of growing revenues over that time.
Turning to the outlook, the next three years should generate growth of 13% each year as estimated by the analysts watching the company. With the industry only predicted to deliver 11% per annum, the company is positioned for a stronger revenue result.
In light of this, it's understandable that Green Thumb Industries' P/S sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.
The Bottom Line On Green Thumb Industries' P/S
While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.
As we suspected, our examination of Green Thumb Industries' analyst forecasts revealed that its superior revenue outlook is contributing to its high P/S. It appears that shareholders are confident in the company's future revenues, which is propping up the P/S. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.
The company's balance sheet is another key area for risk analysis. Our free balance sheet analysis for Green Thumb Industries with six simple checks will allow you to discover any risks that could be an issue.
If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:GTII
Green Thumb Industries
Manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States.
Reasonable growth potential with adequate balance sheet.